Moreover, both previous research and the results of our study indicated that in BC samples with TP53 mutations, the expression levels of LDHA, ENO1, and PKM2 were significantly higher than in BC samples with wild-type TP53 (60, 61). This evidence concerns the gene ENO1 and breast cancer.